Song Shishengnan, Wang Chong, Chen Yangchao, Zhou Xiaorong, Han Yi, Zhang Haijian
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
Department of Thoracic Surgery, Beijing Chest Hospital Affiliated to Capital Medical University (Beijing Tuberculosis and Thoracic Tumor Research Institute), 9 Beiguan Street, Tongzhou, 101149, Beijing, China.
Cancer Immunol Immunother. 2025 Feb 1;74(3):92. doi: 10.1007/s00262-024-03936-7.
The amazing diversity of B cells within the tumor microenvironment is the basis for the diverse development of B cell-based immunotherapies. Here, we focus on elucidating the mechanisms of tumor intervention mediated by four tumor-infiltrating B lymphocytes. Naive B cells present the initial antigen, germinal center B cell subsets enhance antibody affinity, and immunoglobulin subtypes exert multiple immune effects, while regulatory B cells establish immune tolerance. Together they reflect the complexity of the changing dynamics of cancer immunity. Additionally, we have investigated the dynamic effects of tumor-infiltrating B lymphocytes in immunotherapy and their relationship to prognosis, providing new insights into potential treatment strategies for patients.
肿瘤微环境中B细胞惊人的多样性是基于B细胞的免疫疗法多样化发展的基础。在此，我们专注于阐明四种肿瘤浸润性B淋巴细胞介导的肿瘤干预机制。初始B细胞呈递初始抗原，生发中心B细胞亚群增强抗体亲和力，免疫球蛋白亚型发挥多种免疫效应，而调节性B细胞建立免疫耐受。它们共同反映了癌症免疫动态变化的复杂性。此外，我们研究了肿瘤浸润性B淋巴细胞在免疫治疗中的动态效应及其与预后的关系，为患者潜在的治疗策略提供了新的见解。
